You are here

Dual Formulation of Atropine/Scopolamine with Enhanced Stability

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: W911QY-20-C-0002
Agency Tracking Number: C2-0551
Amount: $550,896.96
Phase: Phase II
Program: SBIR
Solicitation Topic Code: CBD181-005
Solicitation Number: 18.1
Solicitation Year: 2018
Award Year: 2020
Award Start Date (Proposal Award Date): 2020-01-15
Award End Date (Contract End Date): 2021-01-14
Small Business Information
737 Concord Avenue
Cambridge, MA 02138
United States
DUNS: 557201394
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Xinhua Li
 EVP Chemistry
 (617) 621-8500
Business Contact
 Peter Howe
Phone: (617) 621-8500
Research Institution

The standard US military treatment for nerve agent exposure is application of up to three autoinjectors, each containing atropine sulfate and 2-pralidoxime, to counteract symptoms of nerve agent intoxication and restore acetylcholinesterase activity. This treatment increases survival rates after nerve agent exposure, however, seizures resulting from nerve agent poisoning are a common symptom that can prolong recovery and reduce survival rates. The motion-sickness drug scopolamine hydrobromide, has been demonstrated as an effective treatment for reducing seizures and enhancing survival and recovery from nerve agent exposure. A rapidly injectable solution with a combined formulation of atropine and scopolamine would be extremely beneficial to our warfighters and first responders; however, a stable dual formulation of atropine and scopolamine has not been demonstrated. We propose to develop stable formulations containing atropine sulfate and scopolamine hydrobromide. The dual formulations containing both drugs will be stable for a minimum of 2 years with a volume of 2 mL or less.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government